A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02